



## Multiple Myeloma

### Syndicated Thought Leader Insight

# Thought Leader Insight & Analysis Report Multiple Myeloma Q1 2011

<b>Therapeutic Class:</b>	Oncology/Hematology
<b>Focus Area:</b>	Multiple Myeloma
<b>Specialty/Location:</b>	Hematologists/N. America, Europe
<b>Number of Interviews:</b>	6
<b>Number of Pages:</b>	145
<b>Publication Date:</b>	February 2011
<b>Principal Authors:</b>	Kim Grant Tricia L. Hanlon Jeffrey D. Berk, Ph.D., MBA
<b>Product Code:</b>	MHOMQ111-25
<b>Pricing:</b>	\$7,500
<b>Order Info:</b>	www.medpredict.com or call (513) 271-1924

**Abstract:** This new report captures the opinions of six experts (4 US, 1 Italian, 1 German) who specialize in multiple myeloma. They provide insight into the practice-changing ramifications of the data presented at ASH 2010.

Multiple myeloma has been transformed into a chronic but still life threatening disease. Initial response rates to standard of care are very high. Revlimid, Velcade and dexamethasone gives a 100% response rate, with the very good partial response rate being 75%. From a commercial standpoint, this means that the population that can benefit from a new targeted therapeutic monotherapy is going to be negligible. The name of the game is, and will be, combination therapy. With this as a backdrop, some of the topics the Panel tackles include:

- What are the key unmet needs in multiple myeloma?
- How do they differentiate carfilzomib from bortezomib? Pomalidomide from lenalidomide?
- How will safety, efficacy and economics of new combinations drive the choice of therapy?
- Where will other mechanisms fit – including IMiD, HDAC, CS-1, CD38, CD56, CD138, FGFR3, AKT, CD66b, IGF-1, IL6, RAF/MEK, antibody drug conjugates and vaccines?
- What is new in transplant? Use of anticoagulants? Risk stratification? Treatment of skeletal related events?

**Full transcripts of six qualitative interviews with hematologists are included with this report.**

**Companies/compounds discussed in this report:**

<b>Company</b>	<b>Generic</b>	<b>Brand</b>
Amgen	denosumab	Xgeva / Prolia
Bayer-Schering / J&J	rivaroxaban	Xarelto
Bristol-Myers Squibb / Abbott BMS	elotuzumab; HuLuc63 <b>tanespimycin</b>	
Boehringer Ingelheim	dabigatran	Pradaxa
Caris / Signal Genetics	Myeloma Prognostic Risk Signature (MyPRS)	
Celgene	lenalidomide pomalidomide romidepsin	Revlimid Actimid Istodax
Centocor	CNTO-328	
Cephalon	CEP18770	
Genentech	Anti-FGFR3 MAb	
GenMab	daratumumab; HuMax-CD38	
Gentium	defibrotide	Dasovas
GlaxoSmithKline	MAGE-A3 A15	
ImmunoGen BioTest / ImmunoGen	lorvotuzumab; IMG901 BT-062	
Keryx / Aeterna Zentaris	perifosine	
Merck	vorinostat	Zolinza
Millennium	bortezomib MLN-9708	Velcade
Nereus	NPI-0052	
Novartis	zoledronic acid panobinostat dovitinib AUY-922	Zometa
Proteolix / Onyx	carfilzomib	
Southampton University Hospitals NHS Trust	BW 250 / 183 ( <sup>90</sup> Y anti-CD66 radioimmunoconjugate	

## Table of Contents

### EXECUTIVE SUMMARY 4

Report Highlights .....	5
-------------------------	---

### KEY FINDINGS 15

#### Therapeutics .....15

Proteasome Inhibitors .....	15
Velcade; bortezomib (Millennium) .....	15
carfilzomib (Proteolix / Onyx).....	19
CEP18770 (Cephalon) / MLN-9708 (Millennium).....	25
NPI-0052 (Nereus).....	27
IMiD .....	28
Revlimid; lenalidomide (Celgene) / Thalomid; thalidomide (Celgene) .....	28
Actimid; pomalidomide (Celgene).....	36
HDAC .....	42
Zolinza; vorinostat (Merck) .....	43
panobinostat (Novartis).....	48
Istodax; romidepsin (Celgene / Gloucester) .....	51
CS-1 .....	54
elotuzumab; HuLuc63 (Bristol-Myers Squibb / Abbott) .....	54
CD38 .....	58
daratumumab; HuMax-CD38 (GenMab) .....	58
CD56 .....	60
lorvotuzumab; IMG901 (ImmunoGen) .....	60
CD138 .....	62
BT-062 (Biotest / ImmunoGen).....	62
FGFR3 .....	63
dovitinib (Novartis) .....	65
Anti-FGFR3 MAb (Genentech) .....	65
HSP90.....	65
Tanespimycin (Bristol-Myers Squibb).....	66
NVP-AUY922 (Novartis / Vernalis) .....	67
AKT .....	67
Perifosine (Keryx / Aeterna Zentaris) .....	67
CD66b .....	69
BW 250/183 ( <sup>90</sup> Y anti-CD66 radioimmunoconjugate; Southampton Univ. Hospitals NHS Trust) .....	69
IGF-1 .....	70
IL6 .....	71
CNTO-328 (Centocor) .....	71
RAF / MEK .....	71
Vaccines.....	72
MAGE-A3 A15 (GlaxoSmithKline) .....	72

#### Habits & Practice.....72

Standard of Care.....	72
Unmet Need / New Therapeutics .....	79
Risk Stratification .....	82
Myeloma Prognostic Risk Signature (MyPRS) (Signal Genetics / Caris).....	82
PET Scan.....	83
Transplant .....	84
Anticoagulation.....	86

Warfarin, LMWH, Pradaxa (dabigatran), Xarelto (rivaroxaban) .....	86
Dasovas; defibrotide (Gentium) .....	89
Skeletal Related Events .....	91
Xgeva / Prolia (denosumab; Amgen).....	91

**THOUGHT LEADER INTERVIEWS      93**

<b>Interview OHIID02532.....</b>	<b>93</b>
<b>Interview OHIID02533.....</b>	<b>106</b>
<b>Interview OHIID02534.....</b>	<b>116</b>
<b>Interview OHIID02535.....</b>	<b>124</b>
<b>Interview OHIID02537.....</b>	<b>132</b>
<b>Interview OHIID02538.....</b>	<b>139</b>